HORMONAL STATUS IN POSTMENOPAUSAL ANDROGENETIC ALOPECIA
December 1992
in “International Journal of Dermatology”
TLDR No significant hormone differences found in postmenopausal women with androgenetic alopecia.
This study aimed to determine the serum levels of testosterone, estradiol, and sex hormone binding globulin (SHBG) in postmenopausal women with androgenetic alopecia and healthy controls. The results showed no statistically significant differences in hormone levels between the two groups, suggesting that a genetically determined functional alteration of androgen receptors and/or a metabolic disturbance may exist in the hair follicle keratinocytes in androgenetic alopecia. The study contradicts previous findings that reported high serum concentrations of DHEA-S, free testosterone/SHBG, and 3,17-androstanediol glucuronide/SHBG ratios, as well as low SHBG levels in women with androgenetic alopecia.
View this study on onlinelibrary.wiley.com →
Cited in this study
research Androgenic Alopecia
The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.
research Female androgenic alopecia. The 3 alpha,17 beta-androstanediol glucuronide/sex hormone binding globulin ratio as a possible marker for female pattern baldness
Women with more 3α,17β-androstanediol glucuronide compared to sex hormone binding globulin are more likely to have female pattern baldness.
Related
research PLASMA C19 STEROID SULPHATE LEVELS AND INDICES OF ANDROGEN BIOAVAILABILITY IN FEMALE PATTERN ANDROGENIC ALOPECIA
Women with female pattern hair loss have higher levels of certain androgens, suggesting increased androgen exposure to hair follicles.